Patient 5 (V600EBRAF) presented with extensive metastatic disease and was enrolled in the CheckMate 067 trial (anti-PD-1 antibody nivolumab alone versus anti-CTLA-4 antibody ipilimumab alone versus combination of the two). This evidence concerns the gene CTLA4 and metastatic neoplasm.